Immune-mediated Neurodegeneration and Neuroprotection in MS

International MS Journal

Volumn 10, Issue 4, 2003, Pages 122-130

  Giuliani, F ^a   Yong, V W ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE   (Canada)

Author keywords

Axons; Immune mediated damage; Neurodegeneration; Neurons; Neuroprotection; T cells

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; AXONAL INJURY; BRAIN PROTECTION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE MEDIATED INJURY; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE CELL LESION; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS;

EID: 0842334615     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Paly DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662-667.
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661.
3. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.
4. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.
5. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
6. Lucchinetti C, Bruck W, Rodriguez M, Lassmann G. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 800-806.
7. Martin R, Sturzebecher CS, McFarland HF. Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat Immunol 2001; 2: 785-788.
8. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol 1994; 36 (Suppl): S47-S53.
9. Hafler DA, Weiner HL. Antigen-specific immunosuppression: oral tolerance for treatment of autoimmune disease. Chem Immunol 1995; 60: 126-149.
10. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85: 299-302.
11. Wekerle H, Hohlfeld R. Molecular mimicry in multiple sclerosis. N Engl J Med 2003; 349: 185-186.
12. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
13. van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol 2000; 105: 46-57.
14. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254-260.
15. Flugel A, Willem M, Berkowicz T, Wekerle H. Gene transfer into CD4+ T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat Med 1999; 5: 843-847.
16. Qing Z, Sewell D, Sandor M, Fabry Z. Antigen-specific T-cell trafficking into the central nervous system. J Neuroimmunol 2000; 105: 169-178.
17. Charcot M. Histologie de la sclerose en plaques. Gaz Hosp 1868; 141: 554-558.
18. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399.
19. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
20. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56: 1496-1504.
21. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-2212.
22. Tourbah A, Stievenart JL, Gout O, Fontaine B, Liblau R, Lubetzki C et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology 1999; 53: 1091-1097.
23. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126: 433-437.
24. Bagnato F, Jeffries N, Richert ND, Stone RD, Ohayon JM, McFarland HF et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003; 126: 1782-1789.
25. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-793.
26. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001; 49: 793-796.
27. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neural 2002; 52: 650-653.
28. Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003; 60: 1949-1954.
29. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157-1162.
30. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neural 2001; 50: 389-400.
31. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49: 470-476.
32. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999; 28: 114-127.
33. Giuliani F, Goodyer CG, Antel JP, Yong VW. Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol 2003; 171: 368-379.
34. Venters HD, Tang Q, Liu Q, VanHoy RW, Dantzer R, Kelley KW. A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. Proc Natl Acad Sci U S A 1999; 96: 9879-9884.
35. Neumann H, Covalie A, Jenne DE, Wekerle H. Induction of MHC class I genes in neurons. Science 1995; 269: 2582-2590.
36. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992; 29: 243-246.
37. Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of Interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996; 138: 206-213.
38. Toulmond S, Parnet P, Linthorst AC. When cytokines get on your nerves: cytokine networks and CNS pathologies. Trends Neurosci 1996; 19: 409-410.
39. Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995; 26: 676-680; discussion 681.
40. Takahashi JL, Giuliani F, Power C, Imai Y, Yong VW. Interleukin-1 beta promotes oligodendrocyte death through glutamate excitotoxicily. Ann Neurol 2003; 53: 588-595.
41. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50: 169-180.
42. Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002; 8: 532-533.
43. Smith KJ, Hall SM. Factors directly affecting impulse transmission in inflammatory demyelinating disease: recent advances in our understanding. Curr Opin Neurol 2001; 14: 289-298.
44. Garthwaite G, Goodwin DA, Batchelor AM, Leeming K, Garthwaite J. Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience 2002; 109: 145-155.
45. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994; 36: 778-786.
46. Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A 1995; 92: 12041-12045.
47. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123: 1174-1183.
48. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502-511.
49. Vos CM, Sjulson L, Nath A, McArthur JC, Pardo CA, Rothstein J et al. Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol 2000; 163: 324-330.
50. Johnston JB, Zhang K, Silva C, Shalinsky DR, Conant K, Ni W et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001; 49: 230-241.
51. Krekoski CA, Neubauer D, Graham JB, Muir D. Metalloproteinase-dependent predegeneration in vitro enhances axonal regeneration within acellular peripheral nerve grafts. J Neurosci 2002; 22: 10408-10415.
52. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130: 443-454.
53. Mollnes TE, Vandvik B, Lea T, Vartdal F. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J Neurol Sci 1987; 78: 17-28.
54. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43: 465-471.
55. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
56. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002; 168: 458-465.
57. Manning PT, Johnson EMJ. MHC-specific cytotoxic T lymphocyte killing of dissociated sympathetic neuronal cultures. Am J Pathol 1987; 128: 395-409.
58. Rall GF, Mucke L, Oldstone MB. Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class-1 expressing neurons in vivo. J Exp Med 1995; 182: 1201-1212.
59. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class 1-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001; 159: 809-815.
60. Redwine JM, Buchmeier MJ, Evans CF. In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. Am J Pathol 2001; 159: 1219-1224.
61. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. T-cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions. J Exp Med 1992; 175: 993-1002.
62. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002; 81: 1285-1297.
63. Lees GJ. The possible contribution of microglia and macrophages to delayed neuronal death after ischemia. J Neurol Sci 1993; 114: 119-122.
64. Fabian RH, Rea HC. Neuronal toxicity by macrophages in mixed brain cell culture is augmented by anti-neuronal IgG and dependent upon nitric oxide synthesis. J Neuroimmunol 1993; 44: 95-102.
65. Graeber MB, Streit WJ, Kreutzberg GW. Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J Neurosci Res 1988; 21: 18-24.
66. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T-cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5: 49-55.
67. Hauben E, Nevo U, Yoles E, Moalem G, Agranov E, Mor F et al. Autoimmune T-cells as potential neuroprotective therapy for spinal cord injury. Lancet 2000; 355: 286-287.
68. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A et al. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci 2001; 21: 3740-3748.69.
69. Santambrogio L, Benedetti M, Chao MV, Muzaffar R, Kulig K, Gabellini N et al. Nerve growth factor production by lymphocytes. J Immunol 1994; 153: 4488-4495.
70. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189: 865-870.
71. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun 2000; 15: 331-345.
72. Barouch R, Schwartz M. Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity. FASEB J 2002; 16: 1304-1306.
73. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000; 20: 5283-5291.
74. Knoblach SM, Faden AI. Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp Neurol 1998; 153: 143-151.
75. Bethea JR, Nagashima H, Acosta MC, Briceno C, Gomez F, Marcillo AE et al. Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma 1999; 16: 851-863.
76. Bachis A, Colangelo AM, Vicini S, Doe PP, De Bernardi MA, Brooker G et al. Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. J Neurosci 2001; 21: 3104-3112.
77. Karp CL, van Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol 2001; 14: 361-368.
78. Mason JL, Suzuki K, Chaplin DD, Matsushima GK. Interleukin-1 beta promotes repair of the CNS. J Neurosci 2001; 21: 7046-7052.
79. Villoslada P, Hauser SL, Bartke I, Unger J, Heald N, Rosenberg D et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 2000; 191: 1799-1806.
80. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1 -and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 125: 2381-2391.
81. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 2003; 53 (Suppl 3): S87-S97; discussion S97-S99.
82. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000; 97: 7446-7451.
83. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheelwe LA et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A 2001; 98: 3398-3403.
84. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology 2001; 57: 731-733.
85. Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1 a. Multiple Sclerosis Collaborative Research Group. Neurology 2000; 55: 185-192.
86. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
87. Inglese M, Van Waesberghe JH, Rovaris M, Beckmann K, Barkhof F, Hahn D et al. The effect of interferon beta-1 b on quantities derived from MT MRI in secondary progressive MS. Neurology 2003; 60: 853-860.
88. Parry A, Corkill R, Blamire AM, Palace J, Narayanan S, Arnold D et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003; 250: 171-178.
89. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001; 248: 979-986.
90. Byrnes AA, McArthur JC, Karp CL. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neural 2002; 51: 165-174.
91. Chabot S, Yong VW. Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS. Neurology 2000; 55: 1497-1505.
92. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802-808.
93. Perini P, Tiberio M, Sivieri S, Facchinetti A, Biasi G, Gallo P. Inetrleukin-1 receptor antagonist, soluble tumor necrosis facto-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta la. Eur Cytokine Netw 2000; 11: 81-86.
94. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G et al. Interferon beta-1 b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinases-9. Ann Neurol 1996; 40: 853-863.
95. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neural 1996; 40: 846-852.
96. Ozenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredrikson S, Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000; 108: 236-243.
97. Hua LL, Liu JS, Brosnan CF, Lee SC. Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: implications for multiple sclerosis. Ann Neurol 1998; 43: 384-387.
98. Kayhan B, Aharoni R, Arnon R. Glatiramer acetate (Copaxone[R]) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. Immunol Lett 2003; 88: 185-192.